Navigation Links
Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000
Date:8/22/2008

h surrounding communities. MDP has also achieved significant improvements in African laboratory capacity and other research infrastructure, as well as upgrading and reinforcement of professional capacity at its African research sites.

About PRO 2000

PRO 2000 (naphthalene sulfonate polymer) is a topical vaginal microbicide under development to prevent the sexual transmission of HIV and other sexually transmitted diseases.

Forward Looking Statements

Except for the descriptions of historical facts contained herein, this press release contains forward-looking statements that involve risks and uncertainties that could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties are set forth in the Company's filings under the Securities Act of 1933 and the Securities Exchange Act of 1934 under "Risk Factors" and elsewhere, and include, but are not limited to: dependence on the success of SANCTURA, SANCTURA XR, NEBIDO, VANTAS and SUPPRELIN LA; need for additional funds and corporate partners, including for the development of our products; effectiveness of our sales force; competition and its effect on pricing, spending, third-party relationships and revenues; dependence on third parties for supplies, particularly for histrelin, manufacturing, marketing, and clinical trials; risks associated with being a manufacturer of some of our products; risks associated with contractual agreements, particularly for the manufacture and co-promotion of SANCTURA and SANCTURA XR and the manufacture of NEBIDO, VANTAS, SUPPRELIN LA and VALSTAR; reliance on intellectual property and having limited patents and proprietary rights; dependence on market exclusivity, changes in reimbursement policies and/or rates for SANCTURA, SANCTURA XR, VANTAS, SUPPRELIN LA, DELATESTRYL and any future products; acceptance by the healthcare community of our approved products and
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
2. Indevus Announces Submission of New Drug Application
3. Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial
4. Indevus Reports Additional Positive Phase III Trial Data for NEBIDO(R)
5. Indevus Pharmaceuticals Provides Update on PRO 2000 Program
6. Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association
7. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... FREDERICK, Md. , May 23, 2013  BioElectronics ... safe consumer medical devices, comments on the FDA panel ... Public Advisory Panel Reclassification – Pulsed Shortwave Therapy Meeting ... Gaithersburg, MD , USA.  The focus of the ... instructed the panel to focus solely on the application ...
(Date:5/23/2013)... 2013 Halozyme Therapeutics, Inc. (NASDAQ: ... David A. Ramsay as ... Vice President, Corporate Development at Halozyme. ... his established financial management experience and his recent ... our commercial group for the last four years, ...
(Date:5/23/2013)... Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ), ... present a company overview at the Deutsche Bank 38 th ... 2013 at 8:40 a.m. ET in Boston, MA. ... presentation will be available on the "Investors & Media" section ... will be available on the Isis Web site within 48 ...
Breaking Medicine Technology:BioElectronics and Pulsed Shortwave Therapy Make Progress 2Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer 2Isis Pharmaceuticals to Present at the Deutsche Bank 38th Annual dbAccess Health Care Conference 2
... Advanced Life Sciences,Holdings, Inc. (Nasdaq: ADLS ... with the National Institute of Allergy and ... biodefense,research, under which the NIAID will conduct ... as a treatment for,anthrax and other high-priority ...
... Compound, AHLi-11, Slated for IND Filing By ... ... Quark Pharmaceuticals, Inc., a,clinical-stage biopharmaceutical company focused on discovering and,developing novel ... the State University of New York at,Buffalo, Center for Hearing & ...
Cached Medicine Technology:Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents 2Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents 3Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents 4Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss 2Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss 3Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss 4
(Date:5/23/2013)... -- Schools should ensure that kids get at ... to support their health and boost performance in ... Although previous studies show 60 minutes of vigorous ... it,s estimated that only about 50 percent of ... to the report from the Institute of Medicine. ...
(Date:5/23/2013)... (HealthDay News) -- Symptoms of borderline personality disorder ... diagnosis and treatment. But researchers in Canada say ... unique to borderline personality disorder: a tendency to ... "They have difficulty processing facial emotions and will ... said Anthony Ruocco, a clinical neuropsychologist and assistant ...
(Date:5/23/2013)... HealthDay Reporter , , THURSDAY, May 23 (HealthDay News) -- ... badly as methamphetamine or crack cocaine, a new study ... mouth, or ,coke mouth, it is startling to see ... the same," said Dr. Mohamed Bassiouny, a professor of ... in Philadelphia. Methamphetamine, crack cocaine and soda -- ...
(Date:5/23/2013)... -- Although a study in 2012 suggested a ... problems associated with Alzheimer,s disease, three groups of ... duplicate those findings. The teams said their ... since the drug involved in the study, bexarotene ... blood-lipid abnormalities, pancreatitis, headaches, fatigue, weight gain, depression, ...
(Date:5/23/2013)... at Emory Vaccine Center have shown that an immune ... responses in mice against viral infections. , The results ... , "Our findings highlight how IL-21 could be important ... Ata Ur Rasheed Mohammed, PhD, the first author of ... director of the Emory Vaccine Center and a Georgia ...
Breaking Medicine News(10 mins):Health News:U.S. School Kids Should Get Hour of Exercise Daily: Report 2Health News:People With Borderline Personality Disorder May Misinterpret Facial Emotions 2Health News:People With Borderline Personality Disorder May Misinterpret Facial Emotions 3Health News:Diet Soda Habit as Bad for Teeth as Meth Addiction, Study Claims 2Health News:Diet Soda Habit as Bad for Teeth as Meth Addiction, Study Claims 3Health News:Scientists Can't Replicate Surprising Finding on Alzheimer's Treatment 2Health News:Vaccine blackjack: IL-21 critical to fight against viral infections 2
... ... has announced that the recent expansion of its production capabilities for various forms of liquid ... ... Inc., a leading custom manufacturer of dietary supplements and homeopathic drugs, has announced that the ...
... research team led by the University of Colorado at ... may provide researchers with a new means of triggering ... The new results are a big step forward ... suicide process that involves a series of biochemical events ...
... COLUMBUS, Ohio Cancer cells in rapidly growing brain ... die. When energy levels are high, tumor cells grow ... less and migrate more., Researchers at the Ohio State ... Richard J. Solove Research Institute have discovered the switch ...
... ... , ... ... ATLANTA , March 11 In recognition of World Kidney Day today, members of the state,s ...
... N.C. , March 11 bioMerieux – a ... diagnostics – today announced the launch of the first Food ... cost-effective solution in the struggle against vancomycin-resistant enterococci (VRE). chromID ... for the qualitative detection of Enterococcus faecium and ...
... Mustache,Mobile Tour is crossing the country from March to September to help celebrate,those special moments that families share around the dinner table. ... and minerals, can help build,stronger families. , ... , ... ...
Cached Medicine News:Health News:GMP Labs Expands Liquid Nutraceutical Capabilities 2Health News:GMP Labs Expands Liquid Nutraceutical Capabilities 3Health News:Discovery of cellular 'switch' may provide new means of triggering cell death, treating disease 2Health News:Discovery of cellular 'switch' may provide new means of triggering cell death, treating disease 3Health News:Researchers discover brain tumor's 'grow-or-go' switch 2Health News:Researchers discover brain tumor's 'grow-or-go' switch 3Health News:Georgia Kidney Community Recognizes World Kidney Day; Echoes Need for Legislation to Improve Access to Dialysis and Transplant Care 2Health News:Georgia Kidney Community Recognizes World Kidney Day; Echoes Need for Legislation to Improve Access to Dialysis and Transplant Care 3Health News:Georgia Kidney Community Recognizes World Kidney Day; Echoes Need for Legislation to Improve Access to Dialysis and Transplant Care 4Health News:bioMerieux Launches Industry-First Vancomycin-Resistant Enterococci (VRE) Screening Tool 2Health News:bioMerieux Launches Industry-First Vancomycin-Resistant Enterococci (VRE) Screening Tool 3Health News:bioMerieux Launches Industry-First Vancomycin-Resistant Enterococci (VRE) Screening Tool 4Health News:bioMerieux Launches Industry-First Vancomycin-Resistant Enterococci (VRE) Screening Tool 5Health News:The Hispanic got milk? Campaign Visited Dallas to Ask How Moms Saborean el Momento! 2Health News:The Hispanic got milk? Campaign Visited Dallas to Ask How Moms Saborean el Momento! 3
... unique thread design is the ultimate anchor ... to pull out, proven delivery, two sutures ... This provides the orthopedic surgeon a superior ... , ,The TwinFix AB anchor was developed ...
The Mitek BioROC EZ fasteners are PLA implants used for soft tissue reattachment to bone. The BioROC EZ uses Radial Osteo Compression (ROC) design for superior fixation strength. The PLA material abs...
... The Sutureless Mitek ConTack Labral ... an L/DL-PLA washer used for soft ... floating washer adjusts to the bony ... contact. The anchor uses Radial Osteo ...
... a fully absorbable soft tissue anchor designed ... dynamic engagement into cancellous bone, its broad ... tip length provide significant resistance to pullout ... material anchor construction provides the benefits of ...
Medicine Products: